Terms: = Pancreatic cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874
65 results:
1. Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.
McIntyre SM; Preston WA; Walch H; Sharib J; Kundra R; Sigel C; Lidsky ME; Allen PJ; Morse MA; Chen W; Cercek A; Harding JJ; Abou-Alfa GK; O'Reilly EM; Park W; Balachandran VP; Drebin J; Soares KC; Wei A; Kingham TP; D'Angelica MI; Iacobuzio-Donahue C; Jarnagin WR
JCO Precis Oncol; 2024 Feb; 8():e2300534. PubMed ID: 38394469
[TBL] [Abstract] [Full Text] [Related]
2. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
[TBL] [Abstract] [Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
4. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
5. Exploration of NPC2 as a Potential Biomarker for Immunotherapy Using RNA-seq and Protein Data - A New Hypothesis.
Lu W; Li D; Tao F; Chen Q; Fan S; Ma Y; Dong H; Hu Y; Yue C
Endocr Metab Immune Disord Drug Targets; 2023; 23(10):1340-1353. PubMed ID: 37056065
[TBL] [Abstract] [Full Text] [Related]
6. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Rev Esp Patol; 2023; 56(1):32-44. PubMed ID: 36599598
[TBL] [Abstract] [Full Text] [Related]
7. Role of genetic testing in hepatic, pancreatic, and biliary cancers.
Hewitt DB; Aziz H; Brown ZJ; Pawlik TM
Surg Oncol; 2022 Sep; 44():101844. PubMed ID: 36116416
[TBL] [Abstract] [Full Text] [Related]
8. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de-Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Clin Transl Oncol; 2022 Nov; 24(11):2107-2119. PubMed ID: 36008616
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract] [Full Text] [Related]
10. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
[TBL] [Abstract] [Full Text] [Related]
11. Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric idh1 inhibitors.
Vaziri-Gohar A; Cassel J; Mohammed FS; Zarei M; Hue JJ; Hajihassani O; Graor HJ; Srikanth YVV; Karim SA; Abbas A; Prendergast E; Chen V; Katayama ES; Dukleska K; Khokhar I; Andren A; Zhang L; Wu C; Erokwu B; Flask CA; Zarei M; Wang R; Rothermel LD; Romani AMP; Bowers J; Getts R; Tatsuoka C; Morton JP; Bederman I; Brunengraber H; Lyssiotis CA; Salvino JM; Brody JR; Winter JM
Nat Cancer; 2022 Jul; 3(7):852-865. PubMed ID: 35681100
[TBL] [Abstract] [Full Text] [Related]
12. Laparoscopic liver resection can be performed safely without intraoperative drain placement.
Sugimoto M; Gotohda N; Kudo M; Kobayashi S; Takahashi S; Konishi M
Surg Endosc; 2022 Dec; 36(12):9019-9031. PubMed ID: 35680665
[TBL] [Abstract] [Full Text] [Related]
13. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary cancers Treated With Platinum-Based Chemotherapy.
Uson Junior PLS; Majeed U; Yin J; Botrus G; Sonbol MB; Ahn DH; Starr JS; Jones JC; Babiker H; Inabinett SR; Wylie N; Boyle AWR; Bekaii-Saab TS; Gores GJ; Smoot R; Barrett M; Nagalo B; Meurice N; Elliott N; Petit J; Zhou Y; Arora M; Dumbauld C; Barro O; Baker A; Bogenberger J; Buetow K; Mansfield A; Mody K; Borad MJ
JCO Precis Oncol; 2022 Jun; 6(1):e2100274. PubMed ID: 35666960
[TBL] [Abstract] [Full Text] [Related]
14. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
[TBL] [Abstract] [Full Text] [Related]
15. Reconstruction and Exploratory Analysis of mTORC1 Signaling Pathway and Its Applications to Various Diseases Using Network-Based Approach.
Buddham R; Chauhan S; Narad P; Mathur P
J Microbiol Biotechnol; 2022 Mar; 32(3):365-377. PubMed ID: 35001007
[TBL] [Abstract] [Full Text] [Related]
16. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
[TBL] [Abstract] [Full Text] [Related]
17. Design of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function.
Rizzuti B; Lan W; Santofimia-Castaño P; Zhou Z; Velázquez-Campoy A; Abián O; Peng L; Neira JL; Xia Y; Iovanna JL
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680086
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
[TBL] [Abstract] [Full Text] [Related]
19. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Xavier MA; Rezende F; Titze-de-Almeida R; Cornelissen B
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439854
[TBL] [Abstract] [Full Text] [Related]
20. A pan-cancer perspective analysis reveals the opposite prognostic significance of CD133 in lower grade glioma and papillary renal cell carcinoma.
Wang H; Wang X; Xu L; Zhang J; Cao H
Sci Prog; 2021; 104(2):368504211010938. PubMed ID: 33878963
[TBL] [Abstract] [Full Text] [Related]
[Next]
